Insulet Corporation PODD SPXR3KPHARMA

Q: What is the current share price of Insulet Corporation (PODD)?

As of 2026-09-07 16:24 PDT, Insulet Corporation (PODD) trades at $147.48 on NasdaqGS. Its 52-week range is $133.26 to $352.82.

Q: What is the market capitalisation of PODD?

Insulet Corporation (PODD) has a market capitalisation of $10.23B on NasdaqGS.

Q: What is the P/E ratio of PODD?

PODD trades at a trailing price-to-earnings (P/E) ratio of 27.62. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 6.88.

Q: What is the return on equity (ROE) of PODD?

PODD has a return on equity (ROE) of 26.02%. Its return on capital employed (ROCE) is 18.87%.

Q: Is PODD a good stock to buy?

This page provides a data-driven analysis of Insulet Corporation (PODD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Medical Devices · United States

https://www.insulet.com

Company Profile ↓

$147.48

-52.22% 1Y

Mkt Cap$10.23B

P/E27.62

P/B6.88

52W High$352.82

52W Low$133.26

Book Value$20.52

EPS (TTM)$5.34

Company Overview

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 26.0%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 18.9%.

Consistent Profit Growth

Net profit has compounded at 105.2% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 26.1% CAGR over the past five years.

Healthy Margins

Operating margin of 16.2% supports profitability.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $2.71B (+30.7% YoY); net profit $247.10M.
Trailing 12 Months Year-on-year growth — revenue +23.5%, earnings +328.6%.
5-Year Trend Long-term compounding — revenue CAGR 26.1%, profit CAGR 105.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	26.13%
1 Year:	23.50%

Compounded Profit Growth

5 Years:	105.15%
1 Year:	328.60%

Stock Price Performance

1 Year:	-52.22%
6 Months:	-37.77%
3 Months:	-3.75%
1 Month:	+5.87%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 6% of range

$133.26 $352.82

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
RSI (14)47.89 · Neutral

Price Performance

1M+5.87%

3M-3.75%

6M-37.77%

1Y-52.22%

Valuation vs Sector

P/E of 27.62 is above the sector median of 25.17 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Strong return on equity of 26.0%.
Compounding revenue at 26.1% over 5 years.
Profit CAGR of 105.2% over 5 years.
Generates positive free cash flow.

CONS

Trading 58.2% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

27.62

Industry PE

25.17

Forward P/E

19.07

PEG Ratio

1.17

Book Value

$20.52

Price to Book

6.88

P/S

3.21

EV/EBITDA

16.58

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

26.13%

Profit 5Y

105.15%

Revenue (YoY)

23.50%

Earnings (YoY)

328.60%

Profitability & Returns

ROCE

18.87%

ROE

26.02%

ROA

9.71%

Profit Margin

12.29%

Op Margin

16.18%

Gross Margin

71.08%

EPS (Latest Qtr)

$1.37

EPS (TTM)

$5.34

Balance Sheet & Liquidity

Debt/Equity

0.67

Quick Ratio

1.51

Current Ratio

2.48

Debt

$948.40M

Total Assets

$3.17B

Current Assets

Working Capital

Ownership

Promoter Holding

0.33%

Chg in Prom Hold

0.00%

FII / Inst Holding

107.01%

Chg in FII Hold

-0.07%

Financial Snapshot

Enterprise Value

$10.23B

Total Revenue (TTM)

$3.05B

EBITDA

$614.90M

Free Cash Flow

$236.90M

Operating Cash Flow

$511.20M

Shares Outstanding

69.35M

Gross Margin

71.08%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	PODD Insulet Corporation SPXR3KPHARMA	147.48	27.62	$10.23B	0.00%	18.87%	26.02%	26.13%	105.15%
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,149.36	38.57	$1.02T	0.58%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	275.23	31.97	$663.28B	2.09%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	256.46	72.45	$453.19B	2.84%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	150.33	120.26	$371.29B	2.65%	-	34.70%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	397.14	25.54	$356.47B	2.33%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	159.99	24.20	$304.10B	3.03%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	162.70	24.36	$252.33B	1.98%	15.97%	21.96%	9.82%	45.96%
9	AMGN Amgen Inc. NDXSPXR3KPHARMA	437.23	27.14	$235.98B	2.49%	13.95%	91.47%	5.51%	5.55%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-	-	-	-	-	101.71M	109.76M	121.78M	130.52M	123.60M	124.20M	151.10M	164.90M	159.60M	177.10M	192.10M	209.40M	198.00M	226.30M	234.00M	249.50M	259.90M	261.80M	247.00M	243.90M	281.90M	261.30M	-	-	-	-	-	-	-	-	-	-
Gross Profit	29.19M	30.52M	31.57M	41.99M	44.05M	50.46M	55.64M	60.94M	59.40M	64.64M	73.62M	79.51M	75.80M	82.10M	102.00M	110.30M	106.70M	116.40M	123.10M	134.10M	126.90M	142.50M	151.80M	167.50M	182.70M	188.70M	209.70M	190.30M	188.30M	240.50M	264.90M	293.30M	306.80M	330.90M	377.10M	409.00M	452.20M	510.10M	529.10M	562.60M
Operating Income	-7.27M	-14.06M	-14.79M	-12.62M	-7.70M	-1.29M	2.42M	-4.13M	-5.31M	-3.36M	2.05M	-768.00K	0	4.33M	6.87M	16.23M	7.30M	7.60M	17.00M	-	7.50M	27.50M	23.80M	16.30M	26.30M	33.70M	37.90M	-26.70M	2.90M	27.70M	31.10M	54.80M	56.90M	54.50M	88.10M	88.80M	121.10M	117.70M	122.10M	129.70M
Net Income	-11.83M	-15.43M	-18.93M	-27.33M	-12.48M	-4.20M	-3.08M	-9.12M	-9.98M	-7.77M	-2.23M	-6.86M	-6.60M	-1.70M	1.70M	9.90M	4.40M	1.40M	800.00K	5.00M	-2.10M	14.40M	11.60M	0	-25.00M	12.60M	27.80M	-35.00M	-5.20M	23.80M	27.30M	51.90M	51.50M	188.60M	77.50M	35.40M	22.50M	87.60M	91.10M	95.00M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-0.04	-	-0.11	-0.03	0.03	0.16	0.07	0.02	0.01	0.08	-0.03	0.22	0.17	0.00	-0.37	0.18	0.40	-0.50	-0.08	0.34	0.39	0.74	0.73	2.59	1.08	0.50	0.32	1.24	1.30	1.37
R&D Expense	8.21M	12.07M	10.04M	-	12.99M	12.95M	13.73M	-	17.50M	18.03M	20.14M	-	20.27M	18.80M	22.34M	-	32.50M	33.00M	31.30M	-	35.50M	34.20M	38.80M	40.70M	40.10M	37.50M	43.10M	42.60M	45.00M	50.10M	55.10M	57.80M	50.20M	53.90M	54.90M	59.60M	73.40M	77.20M	89.70M	88.10M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	66.03M	96.97M	152.25M	211.37M	247.08M	231.32M	263.89M	366.99M	463.80M	563.80M	738.20M	904.40M	1.04B	1.06B	1.70B	2.07B	2.71B
Gross Profit	18.30M	43.73M	66.71M	92.34M	112.40M	127.13M	133.27M	211.09M	277.20M	370.20M	480.30M	582.30M	752.10M	805.60M	1.16B	1.45B	1.94B
Operating Income	-59.36M	-38.63M	-42.47M	-35.97M	-29.14M	-8.87M	-48.74M	-10.70M	-7.40M	27.40M	50.00M	51.50M	126.00M	37.60M	220.10M	308.90M	473.80M
Net Income	-72.34M	-61.16M	-45.83M	-51.87M	-44.97M	-51.50M	-73.52M	-28.88M	-26.80M	3.30M	11.60M	6.80M	16.80M	4.60M	206.30M	418.30M	247.10M
Diluted EPS	-	-	-	-	-	-	-	-0.48	-0.46	0.05	0.19	0.10	0.24	0.07	2.94	5.78	3.48
R&D Expense	13.23M	16.57M	21.86M	24.36M	21.77M	27.90M	43.21M	55.71M	75.70M	94.80M	132.30M	146.80M	160.10M	180.20M	205.00M	219.60M	301.10M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Jun 2011	Sep 2011	Dec 2011	Mar 2012	Jun 2012	Sep 2012	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Jan 2018	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	156.23M	238.75M	228.34M	221.32M	215.68M	203.68M	203.38M	198.06M	287.95M	297.18M	275.13M	456.65M	816.74M	840.00M	928.70M	1.14B	1.87B	2.05B	2.25B	2.59B	3.09B	3.19B
Total Equity	28.11M	61.91M	66.23M	105.44M	94.78M	82.73M	70.22M	59.09M	50.45M	44.18M	124.60M	83.83M	34.05M	63.10M	158.50M	178.88M	212.10M	75.90M	603.60M	556.30M	476.40M	732.70M	1.21B	1.52B
Cash & Equivalents	56.66M	128.00M	113.27M	-	-	93.95M	-	-	-	57.29M	149.73M	151.19M	122.67M	137.17M	272.58M	-	113.90M	213.70M	907.20M	-	-	-	-	-
Long Term Debt	-	-	69.43M	-	-	108.54M	-	-	-	103.73M	113.65M	164.02M	171.70M	332.77M	566.17M	-	592.00M	887.90M	1.04B	1.25B	1.37B	-	-	-
Total Liabilities	-	-	90.00M	133.31M	133.56M	138.59M	145.46M	144.59M	152.93M	153.88M	163.36M	213.35M	241.07M	393.50M	658.23M	661.12M	716.60M	1.07B	1.27B	1.49B	1.77B	1.86B	1.88B	1.68B
Current Liabilities	-	-	18.95M	-	-	28.00M	-	-	-	48.29M	42.37M	44.30M	65.16M	55.70M	86.03M	88.65M	115.70M	157.70M	207.80M	228.80M	364.70M	451.20M	528.40M	680.10M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-49.32M	-35.62M	-25.45M	-29.06M	3.35M	8.92M	-12.55M	15.91M	41.30M	35.90M	98.40M	84.00M	-68.10M	119.00M	145.70M	430.20M	569.30M
Investing Cash Flow	-3.14M	-6.55M	-48.97M	-10.99M	-7.31M	-11.49M	-15.32M	-178.01M	-210.80M	-184.50M	-73.60M	14.00M	-82.70M	-191.10M	-119.40M	-146.20M	-222.70M
Financing Cash Flow	123.80M	27.45M	55.10M	3.39M	96.39M	4.03M	-371.00K	176.57M	304.50M	-8.70M	73.50M	605.50M	40.70M	-40.30M	-13.60M	-28.00M	-595.30M
Capital Expenditure	-3.14M	-6.55M	-11.11M	-10.99M	-7.31M	-11.49M	-10.61M	-22.11M	-73.80M	-157.40M	-163.70M	-129.00M	-111.90M	-122.90M	-75.60M	-124.90M	-191.60M
Free Cash Flow	-52.46M	-42.17M	-36.57M	-40.05M	-3.96M	-2.57M	-23.16M	-6.20M	-32.50M	-121.50M	-65.30M	-45.00M	-180.00M	-3.90M	70.10M	305.30M	377.70M
Share Buybacks	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	59.60M

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	27.7%	45.1%	43.8%	43.7%	45.5%	55.0%	50.5%	57.5%	59.8%	65.7%	65.1%	64.4%	72.3%	76.3%	68.3%	69.8%	71.6%
Operating Margin %	-89.9%	-39.8%	-27.9%	-17.0%	-11.8%	-3.8%	-18.5%	-2.9%	-1.6%	4.9%	6.8%	5.7%	12.1%	3.6%	13.0%	14.9%	17.5%
Net Margin %	-109.6%	-63.1%	-30.1%	-24.5%	-18.2%	-22.3%	-27.9%	-7.9%	-5.8%	0.6%	1.6%	0.8%	1.6%	0.4%	12.2%	20.2%	9.1%
ROE %	-116.9%	-92.3%	-55.4%	-117.4%	-36.1%	-61.4%	-215.9%	-45.8%	-16.9%	1.6%	15.3%	1.1%	3.0%	1.0%	28.2%	34.5%	16.3%
ROCE %	-	-28.1%	-22.0%	-24.0%	-11.9%	-3.5%	-23.2%	-2.7%	-1.0%	3.4%	5.1%	3.1%	6.9%	2.0%	10.3%	12.1%	18.9%

Shareholding Pattern

Insiders

0.33%

Institutions

107.01%

Public Float

107.36%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	9.65%	6.69M	$970.95M
2	Vanguard Capital Management LLC	6.52%	4.53M	$656.76M
3	State Street Corporation	4.61%	3.20M	$464.06M
4	Vanguard Portfolio Management LLC	4.44%	3.08M	$446.41M
5	AQR Capital Management, LLC	3.54%	2.46M	$356.31M
6	BAILLIE GIFFORD & CO	2.94%	2.04M	$296.40M
7	Geode Capital Management, LLC	2.89%	2.00M	$290.82M
8	Two Sigma Investments, LP	2.74%	1.90M	$276.29M
9	Invesco Ltd.	2.44%	1.69M	$245.94M
10	T. Rowe Price Investment Management, Inc.	2.18%	1.51M	$219.46M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PODD

Google News Wed, 02 Sep 2026

Insulet (PODD) Stock May Be 40% Undervalued On Fair Value Grounds - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxPQzlvdWdYWUtJSDdfcW9lVGFPNzNFZEJueUhQYzA3YUc4RnlKM2VCUDJOZXhObTZvSmxrN0hLaW9PU0FIdWdUWjZWZVpQQ1hsLUZYYXp0RWw5OC1ldnpOZVBPNUkwSTZ6RkRjTUk5MUN5RnNDOGVsemZEWEpVdEpDN083ajYtekQzVHZNeW…

Google News Wed, 05 Aug 2026

Why Insulet (PODD) Shares Are Sliding Today - StockStory

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxOME16VHZJUWxwbFJMVWh0cFpIY3hRMFd2LXI3eVdqd3dwazJuMV9sdC1xbXRVanNnRDNKSnNDNFhkSmhvOU4tYk5uSk9MQ2VHOVB2QW1STkNUV2NXZXBMTUtzeE1IVmJxVzhEY0RJazg2NFNicnpleWFSeVZQaGlBY1BscWJXNkZ0NVA2Rl…

Google News Sun, 06 Sep 2026

Should Insulet’s Strong Quarter but Cautious Outlook Require Action From Insulet (PODD) Investors? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxOQmNaYmVjMlptZktaM0hDSXhsSnoyTnd2bk13TXRNUTVZVHZhSTNVMDdkcXcwTjEwWXk5MnpkQkwzZlhUb3hORjdIZEJoZUlLOVBlanNyV01OQ0EzZXhWcHpsWU1ZUTdNajIyQVUzcjNmdndnZ1M4cTY0emQwU2xLTVFOMFNfNTFfeUd3MD…

Google News Wed, 19 Aug 2026

PODD Deadline Alert: Levi & Korsinsky Reminds Insulet Corporation (PODD) Investors of Securities Class Action Deadline on August 31, 2026 - PR Newswire

<a href="https://news.google.com/rss/articles/CBMilwJBVV95cUxOeGJrVjctRzZTZlBOeHNMa3FTVGZ4QW9fTmxQY1JtanNWMGVYZEFuaFlfWERiYTRlZ09yT1NHZHBUT2phYjk2UDFTNkRoalZlVTBCWHhNaHBjdWNuY3dsX2QtZFVpX21UdUg3ajdmR0cxQlJSLXphSWhzTHdiWUNFS0ZpcXMyWENYbkpYbm…

Google News Mon, 17 Aug 2026

Why Insulet (PODD) Stock Is Down Today - quiverquant.com

<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxQZnh1c2lkTUxkd3dCTV9vTG1PUTcwM1kyTlpmVmpfTWRwQjduUWhyTVcwR3ZCc3pjeU91STkwbHo5X3pwZTE3TVlGc3gxYTRGUTdhNS1wQThtS21xWEJBZVgwLV8wS0t4Yjd6QlpfS0JoRzIzWU5oaVEyemZjUWt4SA?oc=5" target="_…

Google News Fri, 04 Sep 2026

Why Is Insulet (PODD) Up 8.1% Since Last Earnings Report? - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxNbXcyV1c5RGc2OXRDZ0pHRWI5MUtkNDlxN2JCYnMwYlRic1I3eWt4UW5yOVpnV0lvSkFSS3hiSzd6VUdQWU16VDJtdF9BdFBvWFZ0U0x1VnZqRDF6ak1uQmZ0Z29HbEFCMG80VHB4XzJpVV94anlmWEhzN0NHdFcxZkJYbnBoc29UVUVQbl…

PODD — Frequently Asked Questions

What is the current share price of Insulet Corporation (PODD)?

As of 2026-09-07 16:24 PDT, Insulet Corporation (PODD) trades at $147.48 on NasdaqGS. Its 52-week range is $133.26 to $352.82.

What is the market capitalisation of PODD?

Insulet Corporation (PODD) has a market capitalisation of $10.23B on NasdaqGS.

What is the P/E ratio of PODD?

PODD trades at a trailing price-to-earnings (P/E) ratio of 27.62. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 6.88.

What is the return on equity (ROE) of PODD?

PODD has a return on equity (ROE) of 26.02%. Its return on capital employed (ROCE) is 18.87%.

Is PODD a good stock to buy?

This page provides a data-driven analysis of Insulet Corporation (PODD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Insulet Corporation PODD SPXR3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Insulet (PODD) Stock May Be 40% Undervalued On Fair Value Grounds - Yahoo Finance

Why Insulet (PODD) Shares Are Sliding Today - StockStory

Should Insulet’s Strong Quarter but Cautious Outlook Require Action From Insulet (PODD) Investors? - simplywall.st

PODD Deadline Alert: Levi & Korsinsky Reminds Insulet Corporation (PODD) Investors of Securities Class Action Deadline on August 31, 2026 - PR Newswire

Why Insulet (PODD) Stock Is Down Today - quiverquant.com

Why Is Insulet (PODD) Up 8.1% Since Last Earnings Report? - Yahoo Finance

PODD — Frequently Asked Questions

What is the current share price of Insulet Corporation (PODD)?

What is the market capitalisation of PODD?

What is the P/E ratio of PODD?

What is the return on equity (ROE) of PODD?

Is PODD a good stock to buy?

Explore More